These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 10622224

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. New options for the treatment of advanced ovarian cancer.
    Dunton CJ.
    Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S, Dührsen U, Nückel H.
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [Abstract] [Full Text] [Related]

  • 6. [Topotecan-based combined chemotherapy for refractory or relapsed hematologic malignancies].
    Wu DP, Tang XW, Sun AN, Qiu HY, Fu ZZ, Ma R, Ruan CG.
    Zhonghua Zhong Liu Za Zhi; 2003 Nov; 25(6):599-601. PubMed ID: 14690573
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
    Laport GF, Williams SF.
    Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 10. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR, Zhang YJ, Xie FY, Zheng W, Li HX, Xia YF, Lin TY, Lu TX.
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel P, Quesnel B, Blay JY, Bouabdallah K, Gisselbrecht C.
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [Abstract] [Full Text] [Related]

  • 12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 13. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 14. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [Abstract] [Full Text] [Related]

  • 15. Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
    Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP.
    Cancer; 2004 Jun 01; 100(11):2408-14. PubMed ID: 15160345
    [Abstract] [Full Text] [Related]

  • 16. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
    Ardeshna KM, Kakouros N, Qian W, Powell MG, Saini N, D'Sa S, Mackinnon S, Hoskin PJ, Goldstone AH, Linch DC.
    Br J Haematol; 2005 Aug 01; 130(3):363-72. PubMed ID: 16042685
    [Abstract] [Full Text] [Related]

  • 17. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May 01; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 18. Rituximab therapy for indolent non-Hodgkin's lymphoma.
    Hagenbeek A, Czuczman MS, Ghielmini M, Herold M, Kimby E, Solal-Céligny P, Unterhalt M.
    Anticancer Drugs; 2002 Nov 01; 13 Suppl 2():S11-7. PubMed ID: 12710586
    [Abstract] [Full Text] [Related]

  • 19. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Habermann TM.
    J Clin Oncol; 2008 Oct 20; 26(30):4952-7. PubMed ID: 18606983
    [Abstract] [Full Text] [Related]

  • 20. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
    Tobinai K.
    Cancer Chemother Pharmacol; 2003 Jul 20; 52 Suppl 1():S90-6. PubMed ID: 12819934
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.